1193MO Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2

C.A Shu,K Goto,Y Ohe,B Besse,K Park,Y Wang,F Griesinger,J.C-H Yang,E Felip,R.E Sanborn,R Bernabe Caro,J.M Bauml,J Chen,E Fennema,J Mahoney,L Trani,R.E Knoblauch,M Thayu,B.C Cho

doi:10.1016/j.annonc.2021.08.1798

1193MO Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2

C.A Shu, K Goto + Show 17 more

Open Access

https://doi.org/10.1016/j.annonc.2021.08.1798

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2021
Citations: 15	License type: publisher-specific-oa

Affiliation: Columbia University Irving Medical Center, National Cancer Center Hospital East, Sungkyunkwan University, West China Hospital of Sichuan University, Carl von Ossietzky University of Oldenburg, National Taiwan University, University of Pennsylvania, Yonsei University

#EGFR-mutant Non-small Cell Lung Cancer #Platinum Doublet Chemotherapy + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The combination of amivantamab (ami), an epidermal growth factor receptor (EGFR)-MET bispecific antibody, with the 3rd-generation tyrosine kinase inhibitor lazertinib (laz), yielded a 36% overall response rate (ORR) in the post-osimertinib (osi), chemotherapy-naïve setting (Cho Ann Oncol 2020;31:S813, Oral 1258). The activity of ami + laz after progression on both osi and platinum doublet chemotherapy is unknown.

Full Text